FDA approves drug Wayrilz (Rilzabrutinib) to treat adults with persistent or chronic immune thrombocytopenia

The U.S. Food and Drug Administration (FDA) recently approved Wayriz (rilzabrutinib) tablets for the treatment of adults with persistent or chronic immune thrombocytopenia (ITP). This disease is an immune system abnormality that causes a decrease in platelets, which can cause serious consequences such as bruising and bleeding, so its treatment is particularly important.

Immune thrombocytopenia (ITP) is a relatively complex blood disease whose main feature is a significant decrease in the number of platelets. Normal adult platelet counts range from 150,000 to 450,000 per microliter of blood, but patients with ITP often have platelet counts below this range. This low platelet level makes patients prone to bruises, bleeding and other symptoms when exposed to minor external shocks. In severe cases, it may even lead to internal bleeding or other life-threatening conditions. Therefore, timely and effective treatment is crucial for ITP patients.

At the time ofthe FDA’s approval of Wayriz, a 24-week randomized double-blind parallel group study also received attention. The study was designed to evaluate the safety and effectiveness of Wayriz, specifically looking at the persistence of platelet responses in patients during treatment. The study enrolled 202 patients and randomly divided them into two groups: one group received Wayriz (133 people in total) and the other received a placebo (69 people). The study results showed that during the 24-week treatment period, 31 patients (23%) in the Wayriz group achieved an adequate and durable platelet count response, while no patients in the placebo group achieved this criterion. This result shows that Wayriz has a significant therapeutic effect in improving the number of platelets in ITP patients.

However, the use of any drug comes with certain risks. While approving Wayriz, the FDA also warned that it may increase the risk of serious infections, including infections caused by bacteria, viruses or fungi. In addition, patients may experience some common side effects when receiving Wayriz treatment, such as diarrhea, nausea, headache, abdominal pain, and COVID-19. The emergence of these side effects requires patients to be more cautious when using drugs and conduct treatment under the guidance of a doctor.

ForThe recommended dose of Wayriz is 400 mg taken orally twice daily. During use, if patients experience gastrointestinal symptoms, it is recommended to take it with food to improve drug tolerance. At the same time, patients should be careful to swallow the pills whole with a glass of water when taking the medicine, and never cut, crush or chew the pills. These medication precautions are prerequisites to ensure that the drug exerts its maximum efficacy in the body.

During the treatment ofITP, patient management not only relies on the use of drugs, but also requires regular monitoring of platelet levels and overall health. The doctor will adjust the treatment plan in a timely manner according to the patient's specific situation and provide corresponding support and guidance. At the same time, patients themselves should also increase their understanding of the disease and understand possible symptoms and complications, so as to take preventive measures in daily life to reduce the risk of bleeding.

In short,FDA’s approval of Wayriz provides a new option for ITP treatment. The launch of this new drug not only brings hope to patients, but also provides clinicians with more basis for formulating treatment plans. In the future, with the accumulation of more clinical data and summary of treatment experience, Wayriz is expected to bring safer and more effective treatment effects to more ITP patients.

Reference materials:https://go.drugbank.com/drugs/DB17709